Lana Pine

The rheumatology month in review addresses opioid concerns and promotes holistic care in managing chronic conditions.

cfPWV values were significantly higher in patients with PsA compared with controls, even after adjusting for confounders.

The approvals were based on data from well-controlled studies of the drug in adult patients with PsA and RA.

A significantly greater improvement in total FIQ scores was observed among patients with fibromyalgia receiving rTMS compared with placebo.

A binary logistic regression analysis recognized factors significantly linked to an increased prevalence of gout, including sex, a history of renal disease or diabetes mellitus, and podagra.

Among included RA studies, 83.3% showed significantly better clinical outcomes in patients managed with a T2T strategy compared with usual care.

After initiating treatment with ixekizumab, tender and swollen joint counts, pain, fatigue, and body surface area affected by psoriasis were significantly improved.

Nigil Haroon, MD, PhD, explains how understanding the "window of opportunity" is crucial in treating axial spondyloarthritis.

E. Michael Lewiecki, MD, discusses the significant treatment gap seen in osteoporosis and barriers to care.

An analysis of individual food groups revealed higher intakes of healthy plant foods, including tea, coffee, and whole grains were linked to a lower risk of gout.

Andrew Sharobeem, DO, discusses the major unmet needs among patients with Ehlers-Danlos Syndrome, including awareness among healthcare providers.

In an interview with HCPLive, E. Michael Lewiecki, MD, explores the current principles of osteoporosis treatment.

Jason Busse, DC, PhD, discusses the discrepancies and contradictions across guidelines regarding the management of chronic pain.

As disparate representation in pivotal research impacts the outcomes of common diseases like lupus, clinicians and researchers alike are working to foster trust and collaboration with more patients of color.

Jason Busse, DC, PhD, highlights the modest benefits of opioids and therapeutic cannabis in managing chronic pain.

These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.

An IMID diagnosis or use of immunomodulatory medications were not shown to be a significant risk factor of severe COVID-19 outcomes.

These findings can be used to enhance usability of the digital health app and improve outcomes and quality of life among patients with long COVID.

Pain relief and healthcare satisfaction were significantly increased in patients who were educated about their fibromyalgia and received care from a knowledgeable clinician who gave them information and guidance.

Those with coexisting PsA and atopic dermatitis needed to switch to a higher number of biologics to achieve disease control.

The meta-analysis demonstrated gout with high blood uric acid levels significantly increases the risk of experiencing angina attacks.

Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.

Patients in the moderate and high disease activity cohorts reported significantly reduced health state utility values and HRQoL scores compared with the reference cohort.

Patients in the Mediterranean diet group reported improvements in most fibromyalgia measures, including anxiety, fatigue, and disability scores.

At 6 months, patients treated with ReNu exhibited significant reductions in assessed knee pain and maintained patient function compared with controls.

This month's review showcases the ongoing efforts to enhance patient care through innovative treatments and comprehensive management strategies.

Lasso demonstrated advantages in predicting clinical remission in patients with RA treated with TNF, with a specificity of 69.9% and sensitivity of 61.7%.

Patients placed in the intervention group reported significant improvements in gout knowledge levels over time compared with controls throughout the 24-week study period.

Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.

Internal dysbiosis was present in 66% of patients at baseline and was more common among those with a disease duration of > 2 years.